Last checked at 
(Alliance News) - Feedback PLC on Tuesday recorded decreases in its interim results while it focused on advancing its medical imaging communications app Bleepa's proposition.
Bleepa is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework that enables remote and secure communications between front-line clinicians and teams.
The London-based medical imaging technology company reported revenue for the six months ended November 30 was down 39% to GPB165,000 from GBP269,000 in 2019, while pretax loss widened to GPB918,000 from GBP691,000.
Feedback said this was a result of the development and deployment of Bleepa, which included increased investment in software development of GBP672,000, a figure that has more than doubled since 2019. This is in line with its focus on product enhancement linked to market opportunities, it added.
Bleepa is currently being actively used as a tool at The Royal Oldham Hospital in Greater Manchester as part of its response to Covid-19. As at November 30, there were 359 Bleepa users across 10 specialties at Royal Oldham Hospital, an increase of 274 users since completion of the pilot.
The company said it has continued to make "significant" advancements in its transition into the mobile medical communications market by continuing to invest in further augmenting and expanding Bleepa's offering.
Looking ahead, Chief Executive Tom Oakley said: "As the restrictions imposed by the global pandemic subside, we are confident in our ability to build on the strong foundations we have now laid, and to deliver the next key milestones for the company. Feedback is continuing commercial discussions, and while the pandemic slowed progression of Bleepa within the NHS, we are now seeing improvement in the pace of these talks, as well as a growing interest outside of the NHS and internationally."
Shares in Feedback were up 2.3% at 1.10 pence in London on Tuesday.
By Zoe Wickens; zoewickens@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
